Trial · NCT04856930
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | -5.9 | Standard Deviation 6.05 | count of abscess and inflammatory nodule | |
| Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | -4.1 | Standard Deviation 4.63 | count of abscess and inflammatory nodule | |
| Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Placebo | -5.6 | Standard Deviation 7.40 | count of abscess and inflammatory nodule | |
| Percent Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | -44.7 | Standard Deviation 39.23 | percent change | |
| Percent Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | -36.7 | Standard Deviation 36.59 | percent change | |
| Percent Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Placebo | -41.2 | Standard Deviation 43.69 | percent change | |
| Number of Participants Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50): Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | 16 | Participants | ||
| Number of Participants Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50): Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | 16 | Participants | ||
| Number of Participants Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50): Placebo-Controlled Period | Placebo-Controlled Period: Placebo | 15 | Participants | ||
| Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | -0.3 | Standard Deviation 2.89 | units on a scale | |
| Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | -0.7 | Standard Deviation 2.37 | units on a scale | |
| Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Placebo | -0.4 | Standard Deviation 3.22 | units on a scale | |
| Change From Baseline in Average HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | -0.5 | Standard Deviation 2.29 | units on a scale | |
| Change From Baseline in Average HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | -1.0 | Standard Deviation 2.48 | units on a scale | |
| Change From Baseline in Average HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Placebo | -0.5 | Standard Deviation 2.74 | units on a scale | |
| Percent Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | 7.6 | Standard Deviation 81.81 | percent change | |
| Percent Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | 10.2 | Standard Deviation 146.92 | percent change | |
| Percent Change From Baseline in Worst HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Placebo | 30.3 | Standard Deviation 136.89 | percent change | |
| Percent Change From Baseline in Average HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 400/200 mg | -1.3 | Standard Deviation 58.54 | percent change | |
| Percent Change From Baseline in Average HS Pain NRS Score at Week 16: Placebo-Controlled Period | Placebo-Controlled Period: Imsidolimab 200/100 mg | -18.3 | Standard Deviation 37.76 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856930/results